Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies.
Yong, K Cavet, James Johnson, P Morgan, G Williams, C Nakashima, D Akinaga, S Oakervee, H Cavenagh, J
Yong, K
Cavet, James
Johnson, P
Morgan, G
Williams, C
Nakashima, D
Akinaga, S
Oakervee, H
Cavenagh, J
Citations
Altmetric:
Abstract
KW-2478 is a novel, non-ansamycin, non-purine heat-shock protein 90 (Hsp90) inhibitor.
Description
Date
2016-01-12
Publisher
Collections
Keywords
Type
Article
Citation
Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies. 2016, 114 (1):7-13 Br J Cancer